These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774 [TBL] [Abstract][Full Text] [Related]
24. Pseudoprogression on bevacizumab treatment: tumor-dynamics in the modern era of systemic treatment for metastatic colorectal cancer. Punt CJA; Huiskens J; van Gulik T; Engelbrecht M Acta Oncol; 2018 May; 57(5):681-682. PubMed ID: 29140135 [No Abstract] [Full Text] [Related]
25. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer. Hsu HC; Liu YC; Wang CW; Chou WC; Hsu YJ; Chiang JM; Lin YC; Yang TS Cancer Med; 2019 Jul; 8(7):3437-3446. PubMed ID: 31090176 [TBL] [Abstract][Full Text] [Related]
26. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Sørbye H; Dahl O Acta Oncol; 2004; 43(5):495-8. PubMed ID: 15360055 [TBL] [Abstract][Full Text] [Related]
27. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer]. Kawakami H; Satoh T; Nakagawa K Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001 [No Abstract] [Full Text] [Related]
28. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378 [TBL] [Abstract][Full Text] [Related]
29. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S; Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366 [TBL] [Abstract][Full Text] [Related]
30. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer]. Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798 [TBL] [Abstract][Full Text] [Related]
32. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A; Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906 [TBL] [Abstract][Full Text] [Related]
33. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180 [TBL] [Abstract][Full Text] [Related]
34. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. McLean J; Rho YS; Kuruba G; Mamo A; Gilabert M; Kavan T; Panasci L; Melnychuk D; Batist G; Kavan P Clin Colorectal Cancer; 2016 Jun; 15(2):135-40. PubMed ID: 26553578 [TBL] [Abstract][Full Text] [Related]
35. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667 [TBL] [Abstract][Full Text] [Related]
36. Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer. Kawahara H; Mouri T; Ishida K; Matsumoto N; Akiba T; Yanaga K Anticancer Res; 2018 Apr; 38(4):2419-2422. PubMed ID: 29599371 [TBL] [Abstract][Full Text] [Related]
37. New possibilities in chemotherapy for colorectal cancer. Bekradda M; Cvitkovic E Ann Oncol; 1999; 10 Suppl 6():105-11. PubMed ID: 10676561 [No Abstract] [Full Text] [Related]
38. The handling of metastatic colorectal cancer. Fornarini G; Guglielmi A; Sobrero A Ann Oncol; 2005; 16 Suppl 2():ii141-3. PubMed ID: 15958445 [No Abstract] [Full Text] [Related]
39. Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen. Kim JH; Choi PR; Park SJ; Park MI; Moon W; Kim SE; Lee GW Korean J Gastroenterol; 2014 Apr; 63(4):209-15. PubMed ID: 24755745 [TBL] [Abstract][Full Text] [Related]